The increasing use of cytotoxic chemotherapy for patients with incurable malignancy has raised a number of practical and ethical dilemmas for health care workers in the fields of oncology and palliative medicine. This paper addresses some of these issues and attempts to suggest basic principles which may contribute to the successful use of palliative chemotherapy.
La Vechhia C. , Levi F., Lucchini F., Garattini S.Progress of anticancer drugs in reducing mortality from selected cancers in Europe: an assessment. Anti-Cancer Drugs1991; 2: 215-21.
2.
Kearsley JHCytotoxic chemotherapy for common adult malignancies: 'The Emperor's New Clothes' revisited? Br Med J1986; 293: 871-76.
3.
Maguire P., Selby P.Assessing quality of life in cancer patients. Br J Cancer1989; 60: 437-40.
4.
Kearsley JHCompromising between quantity and quality of life. In: Stoll BA ed. Ethical dilemmas in cancer care. Hong Kong: Macmillan1989; 39-49.
5.
Leonard Rcf.Small cell lung cancer [guest editorial]. Br J Cancer1989; 59: 487-90.
6.
Neidhart JA, Gochnour D., Roach R. et al. A comparison of mitoxantrone and doxorubicin in breast cancer . J Clin Oncol1986; 4: 672-77.
7.
Italian Multicentre Breast Study Group. Phase III randomized study of fluorouracil, epiribicin, and cyclophosphamide vs. fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol1988; 6: 976-82.
8.
Alberts DS, Mason-Liddil N.Carboplatin in the treatment of ovarian cancer. Semin Oncol1989; 16: 19-26.
9.
Baker LH, Vaughan CB, Al-Sarraf M. et al. Evaluation of combination versus sequential cytotoxic chemotherapy in the treatment of advanced breast cancer. 1974; 33: 513-17.
10.
Chlebowski RT, Irwin LE, Pugh RP et al. Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res1979; 39: 4503-506.
11.
Chlebowski RT, Smalley RV, Weiner LE et al. Combination versus sequential single agent chemotherapy in advanced breast cancer: association with metastatic sites and long-term survival. Br J Cancer1989; 59: 227-30.
12.
Slevin MLQuality of life: philosophical question or clinical reality? Br Med J1992; 305: 466-69.
13.
Gruppo Interegionale Cooperativo Oncologico Ginecologia. A randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet1987; ii: 353-59.
14.
Harris AL, Cantwell BM, Carmichael J. et al. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet1990; 335: 186-90.
15.
Muss HB, Case LD, Richards F. et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med1991 ; 325: 1342-48.
16.
Coates A., Gebski V., Bishop JF et al. Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med1987; 317: 1490-95.
17.
Spiro SG, Souhami R., Geddes DM et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign Trial. Br J Cancer1989; 59: 578-83.
18.
Carbone PPHigh-dose chemotherapy for breast cancer [editorial]. J Clin Oncol1987; 5: 167-68.
19.
Klein LAProstatic carcinoma. N Engl J Med1979; 300 : 824-33.
20.
Horwitz KB, Koseki Y., McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology1978; 103: 1742-51.
21.
Kelley RM, Baker WHProgestational agents in the treatment of carcinoma of the endometrium. N Engl J Med1961; 264: 216-22.
22.
Langdon SP, Hawkes MM, Lawrie SS et al. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. BrJ Cancer1990; 62: 213-16.
23.
Somers KD, Koenig M., Schechter GLGrowth of head and neck squamous cell carcinoma in nude mice: potentiation of laryngeal carcinoma by 17β-estradiol. J Natl Cancer Inst1989; 80: 688-91.
24.
Allegra JCIntroduction to the second international conference on the management of hormone-responsive tumors. Semin Oncol1985; 12 (1 suppl 1): 2.
25.
McClay EF, Mastrangelo MJ, Bellet RE et al. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep1987 ; 71: 465-69.
26.
Muss HB, Costanzi JJ, Leavitt R. et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol1987; 5: 286-91.
27.
Friedlander ML, Sims K., Kearsley JHImpairment of recall improves tolerance of cytotoxic chemotherapy. Lancet1983; ii: 686.
28.
Friedlander ML , Kearsley JH, Sims K. et al. Lorazepam as an adjunct to anti-emetic therapy with haloperidol in patients receiving cytotoxic chemotherapy. Aust N Z J Med1983; 13: 53-56.
29.
Marty M.Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting . Eur J Cancer Clin Oncol1989; 25 (suppl 1): 41-45.
30.
Powles TJ, Jones AL, Judson IR et al. A randomized trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer1991; 64: 406-10.
31.
Chlebowski RT, Paroly WS, Pugh RP et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity . Cancer Treat Rep1980; 64: 47-51.
32.
Greco FA, Johnson DH, Hainsworth JDChronic daily administration of oral etoposide. Semin Oncol1990; 17 (1 suppl 2): 71-74.
33.
Macdonald JSContinuous low-dose infusion of fluorouracil: is the benefit worth the cost? J Clin Oncol1989; 7: 412-14.
34.
Nagase M., Nomura T., Nakajima T.Effects of intralesional versus ip administration of cisplatin on squamous cell carcinoma of mice. Cancer Treat Rep1987 ; 71: 825-29.
35.
Howell SB, Zimm S., Markman M. et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy . J Clin Oncol1987; 5: 1607-12.
